Biotech Values

[iwfal]

(I think that ribavirin is almost as guilty), then you might think that this would be beneficial, a delayed start in the use of telaprevir.....

Not likely that ribavirin is almost as guilty as telaprevir for the AE, at least the serious AE:

Grade 3 rash was observed in 7 (6%), 5 (4%), 6 (5%) and 1 (1%) patients in T12/PR24, T24/PR48, T24/P24, and PR48, respectively. Grade 3 anemia was observed in 0 (0%), 7 (6%), 1 (1%) and 1 (1%) patients in T12/PR24, T24/PR48, T24/P24 and PR48, respectively. Eleven (10%), 29 (25%), 10 (9%), and 5 (4%) patients discontinued due to AEs in T12/PR24, T24/PR48, T24/P24, and PR48, respectively.

Note the much greater incidence of rash in the telaprevir arms than in the no-telaprevir arm. Same with the discontinuation due to AEs.